<DOC>
	<DOCNO>NCT02604342</DOCNO>
	<brief_summary>This randomize active-controlled multicenter Phase III open-label study evaluate compare treatment group efficacy alectinib versus chemotherapy participant ALK-positive advanced NSCLC previously treat chemotherapy crizotinib , measure investigator-assessed progression-free survival ( PFS ) evaluate compare treatment group central nervous system ( CNS ) objective response rate ( C-ORR ) participant measurable CNS metastasis baseline , assess Independent Review Committee ( IRC ) .</brief_summary>
	<brief_title>Alectinib Versus Pemetrexed Docetaxel Anaplastic Lymphoma Kinase ( ALK ) -Positive Advanced Non-Small Cell Lung Cancer ( NSCLC ) Participants Previously Treated With Platinum-Based Chemotherapy Crizotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advanced recurrent ( Stage IIIB amenable multimodality treatment ) metastatic ( Stage IV ) NSCLC ALKpositive . ALK positivity must determine validated fluorescence situ hybridization ( FISH ) test ( recommend probe , Vysis ALK BreakApart Probe ) validate immunohistochemistry ( IHC ) test ( recommend antibody , clone D5F3 ) Participant receive two prior systemic line therapy , must include one line platinumbased chemotherapy one line crizotinib Prior CNS leptomeningeal metastasis allow asymptomatic Participants symptomatic CNS metastasis radiotherapy option allow participate study Measurable disease RECIST Version 1.1 prior administration study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 02 For female childbearing potential , negative pregnancy test must obtain within 3 day start study treatment Participants previous malignancy within past 3 year exclude ( curatively treat basal cell carcinoma skin , early gastrointestinal [ GI ] cancer endoscopic resection situ carcinoma cervix ) Participants receive previous ALK inhibitor crizotinib Any GI disorder may affect absorption oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>